JP2018525399A - Cck2r−薬物コンジュゲート - Google Patents

Cck2r−薬物コンジュゲート Download PDF

Info

Publication number
JP2018525399A
JP2018525399A JP2018507646A JP2018507646A JP2018525399A JP 2018525399 A JP2018525399 A JP 2018525399A JP 2018507646 A JP2018507646 A JP 2018507646A JP 2018507646 A JP2018507646 A JP 2018507646A JP 2018525399 A JP2018525399 A JP 2018525399A
Authority
JP
Japan
Prior art keywords
alkyl
cancer
alkenyl
alkynyl
cycloalkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2018507646A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018525399A5 (enExample
Inventor
ガース・エル・パラム
メリッサ・ネルソン
マリリン・ベッツェル
クリスティーナ・エム・ダークセン
ジョセフ・アナンド・レディ
クリストファー・ポール・リーモン
イオンチョ・ラドスラヴォフ・ヴラホフ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Endocyte Inc
Original Assignee
Endocyte Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Endocyte Inc filed Critical Endocyte Inc
Publication of JP2018525399A publication Critical patent/JP2018525399A/ja
Publication of JP2018525399A5 publication Critical patent/JP2018525399A5/ja
Pending legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/55131,4-Benzodiazepines, e.g. diazepam or clozapine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/03Peptides having up to 20 amino acids in an undefined or only partially defined sequence; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07Tetrapeptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/545Heterocyclic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00Preparations for testing in vivo
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/08Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • C07D209/10Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D209/20Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals substituted additionally by nitrogen atoms, e.g. tryptophane
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D243/00Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/10Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D243/121,5-Benzodiazepines; Hydrogenated 1,5-benzodiazepines
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/14Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
JP2018507646A 2015-08-14 2016-08-10 Cck2r−薬物コンジュゲート Pending JP2018525399A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201562205411P 2015-08-14 2015-08-14
US62/205,411 2015-08-14
US201562261227P 2015-11-30 2015-11-30
US62/261,227 2015-11-30
US201662323287P 2016-04-15 2016-04-15
US62/323,287 2016-04-15
PCT/US2016/046292 WO2017030859A1 (en) 2015-08-14 2016-08-10 Cck2r-drug conjugates

Publications (2)

Publication Number Publication Date
JP2018525399A true JP2018525399A (ja) 2018-09-06
JP2018525399A5 JP2018525399A5 (enExample) 2019-09-05

Family

ID=58051970

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018507646A Pending JP2018525399A (ja) 2015-08-14 2016-08-10 Cck2r−薬物コンジュゲート

Country Status (6)

Country Link
US (1) US10500286B2 (enExample)
EP (1) EP3334447A4 (enExample)
JP (1) JP2018525399A (enExample)
CA (1) CA2995371A1 (enExample)
HK (1) HK1257229A1 (enExample)
WO (1) WO2017030859A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024537766A (ja) * 2021-09-28 2024-10-16 パウル・シェラー・インスティトゥート Cck2-rを標的とする化合物による治療および/またはイメージングに対する癌と診断された患者の応答を予測する方法、ならびに癌を選択的に治療および/またはイメージングする方法に使用する化合物

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11229708B2 (en) 2015-12-04 2022-01-25 Seagen Inc. Conjugates of quaternized tubulysin compounds
US11793880B2 (en) 2015-12-04 2023-10-24 Seagen Inc. Conjugates of quaternized tubulysin compounds
KR20230158005A (ko) 2021-03-18 2023-11-17 씨젠 인크. 생물학적 활성 화합물의 내재화된 접합체로부터의 선택적 약물 방출
CN120554245A (zh) * 2025-07-30 2025-08-29 辽宁众辉生物科技有限公司 一种氟吡菌酰胺中间体n-乙酰氧基甲基-2-三氟甲基苯甲酰胺的合成方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013126797A1 (en) * 2012-02-24 2013-08-29 Purdue Research Foundation Cholecystokinin b receptor targeting for imaging and therapy

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7776814B2 (en) * 2002-07-09 2010-08-17 R&D-Biopharmaceuticals Gmbh Tubulysin conjugates
US8431714B2 (en) * 2007-04-16 2013-04-30 University Of Southern California Synthesis of drug conjugates via reaction with epoxide-containing linkers

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013126797A1 (en) * 2012-02-24 2013-08-29 Purdue Research Foundation Cholecystokinin b receptor targeting for imaging and therapy

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
AMINO ACIDS, vol. 41, no. 5, JPN6020020748, 2011, pages 1049 - 1058, ISSN: 0004562622 *
DALTON TRANSACTIONS, vol. 40, no. 23, JPN6020020750, 2011, pages 6144 - 6167, ISSN: 0004562623 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024537766A (ja) * 2021-09-28 2024-10-16 パウル・シェラー・インスティトゥート Cck2-rを標的とする化合物による治療および/またはイメージングに対する癌と診断された患者の応答を予測する方法、ならびに癌を選択的に治療および/またはイメージングする方法に使用する化合物

Also Published As

Publication number Publication date
EP3334447A4 (en) 2019-07-24
US20180228909A1 (en) 2018-08-16
US10500286B2 (en) 2019-12-10
WO2017030859A1 (en) 2017-02-23
CA2995371A1 (en) 2017-02-23
HK1257229A1 (zh) 2019-10-18
EP3334447A1 (en) 2018-06-20

Similar Documents

Publication Publication Date Title
JP7079355B2 (ja) Psma結合性リガンド-リンカー結合体及び使用方法
WO2010045598A2 (en) Psma binding ligand-linker conjugates and methods for using
JP2020502130A (ja) 線維芽細胞活性化タンパク質(fap)標的イメージングおよび治療
CN104797247A (zh) 用于治疗由psma表达细胞引起的疾病的共轭物
US10500286B2 (en) CCK2R-drug conjugates
US20180110871A1 (en) Dual disulfide drug conjugates
JP2011523415A (ja) 新規な二重標的化抗腫瘍複合体
US20200289659A1 (en) Conjugates for treating diseases
JP2021501201A (ja) ステープルペプチドの細胞内送達のためのポリペプチド接合体
US20200323991A1 (en) Pbd conjugates for treating diseases
WO2016089879A1 (en) Conjugates of garftase inhibitors
US10857234B2 (en) Carbonic anhydrase IX inhibitor conjugates and uses thereof
CN111225688A (zh) 靶向碳酸酐酶阳性癌症的基于fbsa的治疗和放射性成像缀合物
JP7027325B2 (ja) 炭酸無水酵素ixを標的とする薬剤および方法
US20160303251A1 (en) Conjugates of garftase inhibitors
JP2021006550A (ja) 炎症の治療のための抗葉酸剤結合体
TW201919682A (zh) 活化Nrf2路徑的新穎化合物
JP2020117509A (ja) 疾患を処置するためのコンジュゲート
HK40031566A (en) Fbsa-based therapeutic and radioimaging conjugates targeting carbonic anhydrase positive cancers
HK40016572A (en) Luteinizing hormone-releasing hormone receptor (lhrh-r) conjugates and uses thereof
HK40016572B (en) Luteinizing hormone-releasing hormone receptor (lhrh-r) conjugates and uses thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190729

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190729

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200616

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200915

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210112

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20210803